64270-99-1

Usage

Uses

Used in Organic Synthesis:
1-(5-METHYL-2-FURYL)ETHANAMINE is used as a building block in organic synthesis for the creation of various chemical compounds. Its furan ring and ethylamine group provide a foundation for the development of new molecules with potential applications in different industries.
Used in Pharmaceutical Industry:
1-(5-METHYL-2-FURYL)ETHANAMINE is used as an intermediate in the synthesis of pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic effects. 1-(5-METHYL-2-FURYL)ETHANAMINE's reactivity and functional groups make it suitable for the creation of novel drug candidates.
Used in Food Industry:
1-(5-METHYL-2-FURYL)ETHANAMINE is used as a flavoring agent in the food industry. Its presence in certain plant and food sources contributes to the unique taste and aroma profiles of various food products. 1-(5-METHYL-2-FURYL)ETHANAMINE's ability to react with other molecules allows for the creation of new flavor compounds, enhancing the sensory experience of food.

InChI:InChI=1/C7H11NO/c1-5-3-4-7(9-5)6(2)8/h3-4,6H,8H2,1-2H3/p+1/t6-/m1/s1

Upstream product

• 1193-79-9 2-acetyl-5-methylfuran 
• 73750-15-9 methyl 5-methyl-2-furyl ketoxime 
• 102022-21-9 N-(5-methylfurfurylidene)-N-(diphenylmethyl)amine 
• 620-02-0 5-Methylfurfural 

Downstream Products

• 1122-43-6 2,6-dimethyl-3-hydroxypyridine 
• 1240143-80-9 N-[1-(5-methyl-2-furyl)ethyl]-2-nitrobenzamide 

Relevant academic research and scientific papers

Reductive amination of ketonic compounds catalyzed by Cp*Ir(III) complexes bearing a picolinamidato ligand

Cp*Ir complexes bearing a 2-picolinamide moiety serve as effective catalysts for the direct reductive amination of ketonic compounds to give primary amines under transfer hydrogenation conditions using ammonium formate as both the nitrogen and hydrogen source. The clean and operationally simple transformation proceeds with a substrate to catalyst molar ratio (S/C) of up to 20,000 at relatively low temperature and exhibits excellent chemoselectivity toward primary amines.

Alkylative Amination of Biogenic Furans through Imine-to-Azaallyl Anion Umpolung

Starting from biogenic furfurals, an operationally simple and scalable condensation-umpolung-alkylation protocol was employed in the synthesis of racemic furfurylamines. Subsequent enzymatic kinetic resolution by ω-transaminase or lipase biocatalysts allows for the preparation of functionalized heterocyclic building blocks from biogenic base chemicals in optically pure form.

Furan ring opening-pyrrole ring closure. A simple route to 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-3-ones

We report here an application of a furan ring opening-Paal-Knorr pyrrole synthesis sequence for the transformation of furfurylamines into 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-3-ones.

OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula 1: or a pharmaceutically acceptable salt thereof, wherein, X, Y, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, Z, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES

Aminothiazole compounds substituted with sulfur-containing groups are represented by the Formula (I), and their pharmaceutically acceptable salts, prodrugs, active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.